Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

NCT01085201 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Lexiscan

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]